Drugs / Ecabet
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00667004 | Mar → Sep 2008 | dry eye syndrome | Bausch & Lomb Incorporated | Completed | No outcome recorded |
| Phase 2 | NCT00370747 | Sep 2006 → Jun 2007 | dry eye syndrome | Bausch & Lomb Incorporated | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00198536 | Apr → Dec 2005 | dry eye syndrome | Bausch & Lomb Incorporated | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT01308177 Comparator | Mar 2011 → Mar 2012 | bleeding disorder, vascular-type, ulcer disease | Samsung Medical Center | Unknown | No outcome recorded |
| — | NCT01039558 Comparator | Dec 2009 → Mar 2011 | gastroesophageal reflux disease | Seoul National University Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ecabet | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01308177 ↗ |
| Known as | Ecabet sodium | “Ecabet sodium (ES)is a widely used mucoprotective agent for the treatment of gastric ulcers.” NCT01308177 ↗ |
| Modality | Small molecule | — CHEMBL2104585 ↗ |
| Route | Other | “Ophthalmic solution in the Study eye four times daily for 90 days.” NCT00370747 ↗ |